ANTHERA PHARMACEUTICALS INC
OOTC:ANTH0.00
USD
+0.00
(+35.00%)
ISIN
US03674U3005
CUSIP
03674U300
Return %
Stock
S&P 500
1Y
-86.50
14.20
3Y
35.00
81.12
5Y
-83.12
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Paul F. Truex
- Full Time Employees
- 21
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- The Pennzoil Building Houston TX United States 77002
- IPO Date
- Mar 2, 2010
- Website
- anthera.com
- Similar Companies
- Business
- Anthera Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products aimed at treating serious diseases associated with inflammation, autoimmune disorders, and exocrine pancreatic insufficiency. The company's core product candidates include Sollpura (liprotamase), a non-porcine investigational pancreatic enzyme replacement therapy in Phase 3 clinical trials for exocrine pancreatic insufficiency; and Blisibimod (A-623), a B-cell activating factor (BAFF) inhibitor in Phase 2 clinical trials for B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy and systemic lupus erythematosus. Anthera also focuses on enzyme replacement therapies and drugs for cardiovascular and autoimmune conditions, including drug candidates such as varespladib methyl (A-002) and varespladib sodium (A-001), which have undergone Phase 2 clinical studies for acute coronary syndrome and acute chest syndrome. Founded in 2004, Anthera Pharmaceuticals is headquartered in Houston, Texas, and operates primarily in the United States with a focus on unmet medical needs within the biopharmaceutical and healthcare sectors. The company holds license agreements with major pharmaceutical firms including Amgen and Eli Lilly, expanding its development capabilities. A key recent strategic advancement includes the acquisition of Sollpura from Eli Lilly, reinforcing its pipeline in pancreatic enzyme replacement therapy. Anthera is advancing commercial development for Sollpura in the U.S. and seeking strategic partnerships for global launches. Recent operational focuses include the Phase 3 registration program for Sollpura in patients with cystic fibrosis-related exocrine pancreatic insufficiency and ongoing clinical programs for Blisibimod addressing lupus and IgA nephropathy. The company continues to emphasize clinical development and commercialization of novel therapies targeting inflammatory and autoimmune diseases, supported by strategic collaborations, venture funding, and a streamlined product portfolio geared towards unmet therapeutic needs in inflammation and enzyme replacement areas.
Company News
AMD and Cerbras Create A New Blueprint For Hardware
SpaceX Lost $1 Trillion In A Week. So Why Did Bond Investors Rush To Lend It $20 Billion?
Weekend Morning Brew: SpaceX and AI IPOs Drive Market Movements
Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes
AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement